nodes	percent_of_prediction	percent_of_DWPC	metapath
Ethosuximide—CYP2E1—Dacarbazine—skin cancer	0.16	0.211	CbGbCtD
Ethosuximide—CYP3A4—Temozolomide—skin cancer	0.115	0.152	CbGbCtD
Ethosuximide—CYP3A4—Imiquimod—skin cancer	0.115	0.152	CbGbCtD
Ethosuximide—CYP3A4—Vismodegib—skin cancer	0.08	0.105	CbGbCtD
Ethosuximide—CYP3A7—Docetaxel—skin cancer	0.0742	0.0976	CbGbCtD
Ethosuximide—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0742	0.0976	CbGbCtD
Ethosuximide—CYP3A4—Vemurafenib—skin cancer	0.0632	0.0832	CbGbCtD
Ethosuximide—CYP3A5—Docetaxel—skin cancer	0.0556	0.0732	CbGbCtD
Ethosuximide—CYP3A4—Docetaxel—skin cancer	0.0217	0.0286	CbGbCtD
Ethosuximide—Rash erythematous—Imiquimod—skin cancer	0.00436	0.0182	CcSEcCtD
Ethosuximide—Abdominal pain upper—Vismodegib—skin cancer	0.00421	0.0175	CcSEcCtD
Ethosuximide—Breast disorder—Vismodegib—skin cancer	0.00416	0.0173	CcSEcCtD
Ethosuximide—Weight decreased—Vismodegib—skin cancer	0.0036	0.015	CcSEcCtD
Ethosuximide—Cerebration impaired—Temozolomide—skin cancer	0.00341	0.0142	CcSEcCtD
Ethosuximide—Gastrointestinal symptom NOS—Fluorouracil—skin cancer	0.00314	0.0131	CcSEcCtD
Ethosuximide—Connective tissue disorder—Vismodegib—skin cancer	0.00313	0.013	CcSEcCtD
Ethosuximide—Malnutrition—Vismodegib—skin cancer	0.00277	0.0115	CcSEcCtD
Ethosuximide—Vaginal haemorrhage—Temozolomide—skin cancer	0.00271	0.0113	CcSEcCtD
Ethosuximide—Aggression—Bleomycin—skin cancer	0.0027	0.0112	CcSEcCtD
Ethosuximide—Muscle spasms—Vismodegib—skin cancer	0.00267	0.0111	CcSEcCtD
Ethosuximide—Lethargy—Imiquimod—skin cancer	0.00248	0.0103	CcSEcCtD
Ethosuximide—Eosinophilia—Vemurafenib—skin cancer	0.00243	0.0101	CcSEcCtD
Ethosuximide—Systemic lupus erythematosus—Docetaxel—skin cancer	0.00241	0.01	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00234	0.00975	CcSEcCtD
Ethosuximide—Irritability—Imiquimod—skin cancer	0.00232	0.00963	CcSEcCtD
Ethosuximide—Disturbance in attention—Temozolomide—skin cancer	0.00231	0.00962	CcSEcCtD
Ethosuximide—Weight decreased—Vemurafenib—skin cancer	0.00222	0.00925	CcSEcCtD
Ethosuximide—Nervous system disorder—Vismodegib—skin cancer	0.00222	0.00923	CcSEcCtD
Ethosuximide—Skin disorder—Vismodegib—skin cancer	0.0022	0.00914	CcSEcCtD
Ethosuximide—Breast disorder—Imiquimod—skin cancer	0.00219	0.00912	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Vemurafenib—skin cancer	0.00217	0.00904	CcSEcCtD
Ethosuximide—Aplastic anaemia—Dactinomycin—skin cancer	0.00208	0.00865	CcSEcCtD
Ethosuximide—Pancytopenia—Imiquimod—skin cancer	0.00199	0.00828	CcSEcCtD
Ethosuximide—Decreased appetite—Vismodegib—skin cancer	0.00197	0.00818	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Vismodegib—skin cancer	0.00195	0.00813	CcSEcCtD
Ethosuximide—Fatigue—Vismodegib—skin cancer	0.00195	0.00812	CcSEcCtD
Ethosuximide—Connective tissue disorder—Vemurafenib—skin cancer	0.00193	0.00804	CcSEcCtD
Ethosuximide—Aplastic anaemia—Temozolomide—skin cancer	0.00188	0.00782	CcSEcCtD
Ethosuximide—Erythema multiforme—Vemurafenib—skin cancer	0.00186	0.00774	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Imiquimod—skin cancer	0.00185	0.00771	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Vismodegib—skin cancer	0.00185	0.0077	CcSEcCtD
Ethosuximide—Eye disorder—Vemurafenib—skin cancer	0.00184	0.00765	CcSEcCtD
Ethosuximide—Abdominal pain—Vismodegib—skin cancer	0.00179	0.00744	CcSEcCtD
Ethosuximide—Mediastinal disorder—Vemurafenib—skin cancer	0.00177	0.00738	CcSEcCtD
Ethosuximide—Rash erythematous—Docetaxel—skin cancer	0.00174	0.00723	CcSEcCtD
Ethosuximide—Mental disability—Temozolomide—skin cancer	0.00174	0.00723	CcSEcCtD
Ethosuximide—Malnutrition—Vemurafenib—skin cancer	0.00171	0.00713	CcSEcCtD
Ethosuximide—Urinary tract disorder—Imiquimod—skin cancer	0.00166	0.00689	CcSEcCtD
Ethosuximide—Connective tissue disorder—Imiquimod—skin cancer	0.00165	0.00686	CcSEcCtD
Ethosuximide—Urethral disorder—Imiquimod—skin cancer	0.00165	0.00684	CcSEcCtD
Ethosuximide—Lethargy—Dactinomycin—skin cancer	0.00164	0.00682	CcSEcCtD
Ethosuximide—Asthenia—Vismodegib—skin cancer	0.00162	0.00675	CcSEcCtD
Ethosuximide—Erythema multiforme—Imiquimod—skin cancer	0.00159	0.0066	CcSEcCtD
Ethosuximide—Euphoric mood—Fluorouracil—skin cancer	0.00159	0.00659	CcSEcCtD
Ethosuximide—Eye disorder—Imiquimod—skin cancer	0.00157	0.00652	CcSEcCtD
Ethosuximide—Diarrhoea—Vismodegib—skin cancer	0.00155	0.00644	CcSEcCtD
Ethosuximide—Immune system disorder—Imiquimod—skin cancer	0.00152	0.00631	CcSEcCtD
Ethosuximide—Mediastinal disorder—Imiquimod—skin cancer	0.00151	0.00629	CcSEcCtD
Ethosuximide—Mental disorder—Imiquimod—skin cancer	0.00147	0.00612	CcSEcCtD
Ethosuximide—Malnutrition—Imiquimod—skin cancer	0.00146	0.00608	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00145	0.00602	CcSEcCtD
Ethosuximide—Vomiting—Vismodegib—skin cancer	0.00144	0.00598	CcSEcCtD
Ethosuximide—Rash—Vismodegib—skin cancer	0.00143	0.00594	CcSEcCtD
Ethosuximide—Dermatitis—Vismodegib—skin cancer	0.00143	0.00593	CcSEcCtD
Ethosuximide—Pancytopenia—Bleomycin—skin cancer	0.00141	0.00588	CcSEcCtD
Ethosuximide—Nervous system disorder—Vemurafenib—skin cancer	0.00137	0.0057	CcSEcCtD
Ethosuximide—Ataxia—Temozolomide—skin cancer	0.00137	0.00569	CcSEcCtD
Ethosuximide—Lethargy—Fluorouracil—skin cancer	0.00137	0.00569	CcSEcCtD
Ethosuximide—Skin disorder—Vemurafenib—skin cancer	0.00136	0.00565	CcSEcCtD
Ethosuximide—Weight decreased—Bleomycin—skin cancer	0.00135	0.00561	CcSEcCtD
Ethosuximide—Nausea—Vismodegib—skin cancer	0.00134	0.00559	CcSEcCtD
Ethosuximide—Agitation—Imiquimod—skin cancer	0.00134	0.00558	CcSEcCtD
Ethosuximide—Pancytopenia—Dactinomycin—skin cancer	0.00132	0.00549	CcSEcCtD
Ethosuximide—Breast disorder—Temozolomide—skin cancer	0.00131	0.00546	CcSEcCtD
Ethosuximide—Irritability—Fluorouracil—skin cancer	0.00128	0.00532	CcSEcCtD
Ethosuximide—Haematuria—Bleomycin—skin cancer	0.00127	0.00527	CcSEcCtD
Ethosuximide—Ataxia—Fluorouracil—skin cancer	0.00126	0.00524	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00124	0.00514	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.00123	0.00511	CcSEcCtD
Ethosuximide—Decreased appetite—Vemurafenib—skin cancer	0.00122	0.00506	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00121	0.00502	CcSEcCtD
Ethosuximide—Fatigue—Vemurafenib—skin cancer	0.00121	0.00501	CcSEcCtD
Ethosuximide—Pancytopenia—Temozolomide—skin cancer	0.00119	0.00496	CcSEcCtD
Ethosuximide—Nervous system disorder—Imiquimod—skin cancer	0.00117	0.00486	CcSEcCtD
Ethosuximide—Skin disorder—Imiquimod—skin cancer	0.00116	0.00482	CcSEcCtD
Ethosuximide—Agranulocytosis—Dactinomycin—skin cancer	0.00116	0.00481	CcSEcCtD
Ethosuximide—Eosinophilia—Fluorouracil—skin cancer	0.00115	0.00477	CcSEcCtD
Ethosuximide—Weight decreased—Temozolomide—skin cancer	0.00114	0.00473	CcSEcCtD
Ethosuximide—Anorexia—Imiquimod—skin cancer	0.00114	0.00473	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.00111	0.00462	CcSEcCtD
Ethosuximide—Pancytopenia—Fluorouracil—skin cancer	0.0011	0.00457	CcSEcCtD
Ethosuximide—Somnolence—Imiquimod—skin cancer	0.00106	0.00441	CcSEcCtD
Ethosuximide—Erythema multiforme—Dactinomycin—skin cancer	0.00105	0.00437	CcSEcCtD
Ethosuximide—Decreased appetite—Imiquimod—skin cancer	0.00104	0.00431	CcSEcCtD
Ethosuximide—Hypersensitivity—Vemurafenib—skin cancer	0.00103	0.00428	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Imiquimod—skin cancer	0.00103	0.00428	CcSEcCtD
Ethosuximide—Fatigue—Imiquimod—skin cancer	0.00103	0.00428	CcSEcCtD
Ethosuximide—Asthenia—Vemurafenib—skin cancer	0.001	0.00417	CcSEcCtD
Ethosuximide—Urinary tract disorder—Temozolomide—skin cancer	0.000993	0.00413	CcSEcCtD
Ethosuximide—Connective tissue disorder—Temozolomide—skin cancer	0.000988	0.00411	CcSEcCtD
Ethosuximide—Lethargy—Docetaxel—skin cancer	0.000987	0.0041	CcSEcCtD
Ethosuximide—Urethral disorder—Temozolomide—skin cancer	0.000986	0.0041	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Imiquimod—skin cancer	0.000975	0.00406	CcSEcCtD
Ethosuximide—Agranulocytosis—Fluorouracil—skin cancer	0.000963	0.00401	CcSEcCtD
Ethosuximide—Diarrhoea—Vemurafenib—skin cancer	0.000957	0.00398	CcSEcCtD
Ethosuximide—Erythema multiforme—Temozolomide—skin cancer	0.000951	0.00396	CcSEcCtD
Ethosuximide—Urticaria—Imiquimod—skin cancer	0.000947	0.00394	CcSEcCtD
Ethosuximide—Abdominal pain—Imiquimod—skin cancer	0.000943	0.00392	CcSEcCtD
Ethosuximide—Eye disorder—Temozolomide—skin cancer	0.00094	0.00391	CcSEcCtD
Ethosuximide—Leukopenia—Bleomycin—skin cancer	0.000929	0.00386	CcSEcCtD
Ethosuximide—Dizziness—Vemurafenib—skin cancer	0.000925	0.00385	CcSEcCtD
Ethosuximide—Ataxia—Docetaxel—skin cancer	0.000909	0.00378	CcSEcCtD
Ethosuximide—Immune system disorder—Temozolomide—skin cancer	0.000908	0.00378	CcSEcCtD
Ethosuximide—Mediastinal disorder—Temozolomide—skin cancer	0.000906	0.00377	CcSEcCtD
Ethosuximide—Vomiting—Vemurafenib—skin cancer	0.000889	0.0037	CcSEcCtD
Ethosuximide—Abdominal pain upper—Docetaxel—skin cancer	0.000883	0.00367	CcSEcCtD
Ethosuximide—Rash—Vemurafenib—skin cancer	0.000882	0.00367	CcSEcCtD
Ethosuximide—Mental disorder—Temozolomide—skin cancer	0.000881	0.00366	CcSEcCtD
Ethosuximide—Dermatitis—Vemurafenib—skin cancer	0.000881	0.00366	CcSEcCtD
Ethosuximide—Hypersensitivity—Imiquimod—skin cancer	0.000878	0.00365	CcSEcCtD
Ethosuximide—Headache—Vemurafenib—skin cancer	0.000876	0.00364	CcSEcCtD
Ethosuximide—Malnutrition—Temozolomide—skin cancer	0.000876	0.00364	CcSEcCtD
Ethosuximide—Breast disorder—Docetaxel—skin cancer	0.000874	0.00363	CcSEcCtD
Ethosuximide—Cramp muscle—Docetaxel—skin cancer	0.000871	0.00362	CcSEcCtD
Ethosuximide—Leukopenia—Dactinomycin—skin cancer	0.000866	0.0036	CcSEcCtD
Ethosuximide—Asthenia—Imiquimod—skin cancer	0.000855	0.00356	CcSEcCtD
Ethosuximide—Nausea—Vemurafenib—skin cancer	0.00083	0.00345	CcSEcCtD
Ethosuximide—Diarrhoea—Imiquimod—skin cancer	0.000816	0.00339	CcSEcCtD
Ethosuximide—Anorexia—Bleomycin—skin cancer	0.000807	0.00336	CcSEcCtD
Ethosuximide—Agitation—Temozolomide—skin cancer	0.000805	0.00335	CcSEcCtD
Ethosuximide—Pancytopenia—Docetaxel—skin cancer	0.000794	0.0033	CcSEcCtD
Ethosuximide—Dizziness—Imiquimod—skin cancer	0.000788	0.00328	CcSEcCtD
Ethosuximide—Leukopenia—Temozolomide—skin cancer	0.000784	0.00326	CcSEcCtD
Ethosuximide—Vomiting—Imiquimod—skin cancer	0.000758	0.00315	CcSEcCtD
Ethosuximide—Weight decreased—Docetaxel—skin cancer	0.000756	0.00314	CcSEcCtD
Ethosuximide—Anorexia—Dactinomycin—skin cancer	0.000753	0.00313	CcSEcCtD
Ethosuximide—Rash—Imiquimod—skin cancer	0.000752	0.00313	CcSEcCtD
Ethosuximide—Dermatitis—Imiquimod—skin cancer	0.000751	0.00312	CcSEcCtD
Ethosuximide—Headache—Imiquimod—skin cancer	0.000747	0.00311	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00074	0.00308	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000739	0.00307	CcSEcCtD
Ethosuximide—Decreased appetite—Bleomycin—skin cancer	0.000736	0.00306	CcSEcCtD
Ethosuximide—Leukopenia—Fluorouracil—skin cancer	0.000722	0.003	CcSEcCtD
Ethosuximide—Nausea—Imiquimod—skin cancer	0.000708	0.00295	CcSEcCtD
Ethosuximide—Nervous system disorder—Temozolomide—skin cancer	0.000701	0.00291	CcSEcCtD
Ethosuximide—Agranulocytosis—Docetaxel—skin cancer	0.000695	0.00289	CcSEcCtD
Ethosuximide—Skin disorder—Temozolomide—skin cancer	0.000694	0.00289	CcSEcCtD
Ethosuximide—Decreased appetite—Dactinomycin—skin cancer	0.000687	0.00286	CcSEcCtD
Ethosuximide—Fatigue—Dactinomycin—skin cancer	0.000681	0.00283	CcSEcCtD
Ethosuximide—Anorexia—Temozolomide—skin cancer	0.000681	0.00283	CcSEcCtD
Ethosuximide—Urticaria—Bleomycin—skin cancer	0.000673	0.0028	CcSEcCtD
Ethosuximide—Urinary tract disorder—Docetaxel—skin cancer	0.000661	0.00275	CcSEcCtD
Ethosuximide—Connective tissue disorder—Docetaxel—skin cancer	0.000657	0.00273	CcSEcCtD
Ethosuximide—Urethral disorder—Docetaxel—skin cancer	0.000656	0.00273	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Dactinomycin—skin cancer	0.000646	0.00269	CcSEcCtD
Ethosuximide—Nervous system disorder—Fluorouracil—skin cancer	0.000646	0.00269	CcSEcCtD
Ethosuximide—Somnolence—Temozolomide—skin cancer	0.000635	0.00264	CcSEcCtD
Ethosuximide—Erythema multiforme—Docetaxel—skin cancer	0.000632	0.00263	CcSEcCtD
Ethosuximide—Anorexia—Fluorouracil—skin cancer	0.000628	0.00261	CcSEcCtD
Ethosuximide—Eye disorder—Docetaxel—skin cancer	0.000625	0.0026	CcSEcCtD
Ethosuximide—Abdominal pain—Dactinomycin—skin cancer	0.000625	0.0026	CcSEcCtD
Ethosuximide—Hypersensitivity—Bleomycin—skin cancer	0.000624	0.0026	CcSEcCtD
Ethosuximide—Decreased appetite—Temozolomide—skin cancer	0.000621	0.00258	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Temozolomide—skin cancer	0.000617	0.00257	CcSEcCtD
Ethosuximide—Fatigue—Temozolomide—skin cancer	0.000616	0.00256	CcSEcCtD
Ethosuximide—Asthenia—Bleomycin—skin cancer	0.000608	0.00253	CcSEcCtD
Ethosuximide—Immune system disorder—Docetaxel—skin cancer	0.000604	0.00251	CcSEcCtD
Ethosuximide—Mediastinal disorder—Docetaxel—skin cancer	0.000603	0.00251	CcSEcCtD
Ethosuximide—Mental disorder—Docetaxel—skin cancer	0.000586	0.00244	CcSEcCtD
Ethosuximide—Somnolence—Fluorouracil—skin cancer	0.000585	0.00243	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Temozolomide—skin cancer	0.000584	0.00243	CcSEcCtD
Ethosuximide—Malnutrition—Docetaxel—skin cancer	0.000582	0.00242	CcSEcCtD
Ethosuximide—Hypersensitivity—Dactinomycin—skin cancer	0.000582	0.00242	CcSEcCtD
Ethosuximide—Decreased appetite—Fluorouracil—skin cancer	0.000572	0.00238	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000568	0.00236	CcSEcCtD
Ethosuximide—Urticaria—Temozolomide—skin cancer	0.000568	0.00236	CcSEcCtD
Ethosuximide—Asthenia—Dactinomycin—skin cancer	0.000567	0.00236	CcSEcCtD
Ethosuximide—Abdominal pain—Temozolomide—skin cancer	0.000565	0.00235	CcSEcCtD
Ethosuximide—Muscle spasms—Docetaxel—skin cancer	0.00056	0.00233	CcSEcCtD
Ethosuximide—Diarrhoea—Dactinomycin—skin cancer	0.000541	0.00225	CcSEcCtD
Ethosuximide—Vomiting—Bleomycin—skin cancer	0.000539	0.00224	CcSEcCtD
Ethosuximide—Rash—Bleomycin—skin cancer	0.000534	0.00222	CcSEcCtD
Ethosuximide—Dermatitis—Bleomycin—skin cancer	0.000534	0.00222	CcSEcCtD
Ethosuximide—Hypersensitivity—Temozolomide—skin cancer	0.000526	0.00219	CcSEcCtD
Ethosuximide—Urticaria—Fluorouracil—skin cancer	0.000523	0.00218	CcSEcCtD
Ethosuximide—Leukopenia—Docetaxel—skin cancer	0.000521	0.00217	CcSEcCtD
Ethosuximide—Asthenia—Temozolomide—skin cancer	0.000513	0.00213	CcSEcCtD
Ethosuximide—Nausea—Bleomycin—skin cancer	0.000503	0.00209	CcSEcCtD
Ethosuximide—Vomiting—Dactinomycin—skin cancer	0.000502	0.00209	CcSEcCtD
Ethosuximide—Rash—Dactinomycin—skin cancer	0.000498	0.00207	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000492	0.00205	CcSEcCtD
Ethosuximide—Diarrhoea—Temozolomide—skin cancer	0.000489	0.00203	CcSEcCtD
Ethosuximide—Hypersensitivity—Fluorouracil—skin cancer	0.000485	0.00202	CcSEcCtD
Ethosuximide—Dizziness—Temozolomide—skin cancer	0.000473	0.00197	CcSEcCtD
Ethosuximide—Nausea—Dactinomycin—skin cancer	0.000469	0.00195	CcSEcCtD
Ethosuximide—Nervous system disorder—Docetaxel—skin cancer	0.000466	0.00194	CcSEcCtD
Ethosuximide—Skin disorder—Docetaxel—skin cancer	0.000462	0.00192	CcSEcCtD
Ethosuximide—Vomiting—Temozolomide—skin cancer	0.000454	0.00189	CcSEcCtD
Ethosuximide—Anorexia—Docetaxel—skin cancer	0.000453	0.00188	CcSEcCtD
Ethosuximide—Rash—Temozolomide—skin cancer	0.000451	0.00187	CcSEcCtD
Ethosuximide—Diarrhoea—Fluorouracil—skin cancer	0.00045	0.00187	CcSEcCtD
Ethosuximide—Dermatitis—Temozolomide—skin cancer	0.00045	0.00187	CcSEcCtD
Ethosuximide—Headache—Temozolomide—skin cancer	0.000448	0.00186	CcSEcCtD
Ethosuximide—Dizziness—Fluorouracil—skin cancer	0.000435	0.00181	CcSEcCtD
Ethosuximide—Nausea—Temozolomide—skin cancer	0.000424	0.00177	CcSEcCtD
Ethosuximide—Somnolence—Docetaxel—skin cancer	0.000422	0.00176	CcSEcCtD
Ethosuximide—Vomiting—Fluorouracil—skin cancer	0.000419	0.00174	CcSEcCtD
Ethosuximide—Rash—Fluorouracil—skin cancer	0.000415	0.00173	CcSEcCtD
Ethosuximide—Dermatitis—Fluorouracil—skin cancer	0.000415	0.00172	CcSEcCtD
Ethosuximide—Decreased appetite—Docetaxel—skin cancer	0.000413	0.00172	CcSEcCtD
Ethosuximide—Headache—Fluorouracil—skin cancer	0.000412	0.00172	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Docetaxel—skin cancer	0.00041	0.00171	CcSEcCtD
Ethosuximide—Fatigue—Docetaxel—skin cancer	0.00041	0.0017	CcSEcCtD
Ethosuximide—Nausea—Fluorouracil—skin cancer	0.000391	0.00163	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Docetaxel—skin cancer	0.000389	0.00162	CcSEcCtD
Ethosuximide—Abdominal pain—Docetaxel—skin cancer	0.000376	0.00156	CcSEcCtD
Ethosuximide—Hypersensitivity—Docetaxel—skin cancer	0.00035	0.00146	CcSEcCtD
Ethosuximide—Asthenia—Docetaxel—skin cancer	0.000341	0.00142	CcSEcCtD
Ethosuximide—Diarrhoea—Docetaxel—skin cancer	0.000325	0.00135	CcSEcCtD
Ethosuximide—Dizziness—Docetaxel—skin cancer	0.000314	0.00131	CcSEcCtD
Ethosuximide—Vomiting—Docetaxel—skin cancer	0.000302	0.00126	CcSEcCtD
Ethosuximide—Rash—Docetaxel—skin cancer	0.0003	0.00125	CcSEcCtD
Ethosuximide—Dermatitis—Docetaxel—skin cancer	0.000299	0.00125	CcSEcCtD
Ethosuximide—Headache—Docetaxel—skin cancer	0.000298	0.00124	CcSEcCtD
Ethosuximide—Nausea—Docetaxel—skin cancer	0.000282	0.00117	CcSEcCtD
